Development and stability study of glibenclamide oral liquid paediatric formulations for the treatment of permanent neonatal diabetes mellitus.

Journal: European journal of hospital pharmacy : science and practice
Published Date: Dec 16, 2015

Abstract

BACKGROUND: Glibenclamide is a second-generation oral sulfonylurea used to treat neonatal permanent diabetes mellitus. It is more effective and safer than the first-generation agents. However, no liquid oral formulation is commercially available and, therefore, it cannot be used for individuals who cannot swallow the solid form.

Authors

  • Pablo Estevez
    Department of Pharmaceutical Technology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina.
  • Oriana Boscolo
    Universidad de Buenos Aires, Argentina.
  • Eduardo Quiroga
    Department of Pharmaceutical Technology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina.
  • Rocio Fernandez Penuto
    Pharmacy Service, Pediatric Hospital J P Garrahan, Buenos Aires, Argentina.
  • Fabián Buontempo
    Universidad de Buenos Aires, Argentina.
  • Valeria Tripodi
    Department of Pharmaceutical Technology, Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina.
  • Silvia Lucangioli
    Universidad de Buenos Aires, Argentina.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals